ENTELLUS MEDICAL, INC. (NASDAQ:ENTL) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
|
ExhibitNo. |
Description |
| 99.1 | Press Release issued August3, 2017 (furnished herewith) |
ENTELLUS MEDICAL INC ExhibitEX-99.1 2 d438392dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ENTELLUS MEDICAL ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS PLYMOUTH,…To view the full exhibit click here
About ENTELLUS MEDICAL, INC. (NASDAQ:ENTL)
Entellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company’s XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company’s PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure.
